Agenus (AGEN) announced that Dr. Richard Goldberg, an internationally recognized expert in gastrointestinal cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab program for patients and guide the company’s regulatory and development strategy as it prepares to re-engage global health authorities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Agenus Inc. (AGEN) Q1 Earnings Cheat Sheet
- Hold Rating on Agenus Amid Promising NEOASIS Trial Results and Strategic Uncertainties
- Biotech Alert: Searches spiking for these stocks today
- Agenus price target lowered to $8 from $11 at B. Riley
- Agenus: Hold Rating Amid Strategic Shifts and Valuation Risks